Joey Chau

Joey has advised on a number of significant M&A transactions, including the following:

2020

• Advantage Partners, on its primary and secondary general partner share sale to, and strategic partnership with, Tokyo Century Corporation
• CICC, as financial adviser to the offeror, SanXing Trade Co., Ltd., in the proposed privatization of Changshouhua Food Company Limited (HKSE: 1006) by way of a scheme of arrangement
• Li & Fung, in US$100 million strategic investment by JD.com
• Huatai Financial Holdings, as financial adviser, in the proposed privatisation of Huarong Investment Stock Corporation Limited (HKSE: 2277) by its controlling shareholder, Huarong International Financial Holdings Limited (HKSE: 993), by way of a scheme of arrangement involving a conditional share exchange offer
• Skyworth Group Limited (HKSE: 00751) in its HK$1,099.84 million voluntary conditional cash offer to buy-back a maximum of 392,800,000 shares at HK$2.80 per share, representing approximately 12.83% of Skyworth Group’s total issued share capital
• Lilly Asia Ventures, in its investment as cornerstone investor in the US$1,000 million initial public offering and listing of Peijia Medical Limited on the Hong Kong Stock Exchange
• GLP Pte. Ltd. and the consortium offeror comprising the Fung family and GLP, in its proposed privatization of Li & Fung, a company listed on the Hong Kong Stock Exchange (HKSE: 494)

2019

• Cushman & Wakefield (NYSE: CWK), a leading global real estate services firm, in the formation of a new asset services company with Vanke Service
• TPV Technology Limited (HKSE: 903, SGX: T18), in its proposed privatisation by China Electronics Corporation by way of a scheme of arrangement and the withdrawal of listing of its shares on the Hong Kong Stock Exchange and the Singapore Exchange
• Nan Fung Group, in its US$110 million acquisition of a minority stake in Hong Kong International Construction Investment Management Group Co., Limited (HKSE: 687)
• Eddingpharm, a Chinese specialty pharmaceutical company, in its debt financing to purchase two legacy antibiotic brands (Ceclor® and Vancocin®), and a manufacturing facility from Eli Lilly and Company (NYSE: LLY) for US$375 million
• Blackstone, in its US$400 million subscription of H shares convertible bonds in Hong Kong-listed YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKSE: 1558)

2018

• Loyal Valley Capital and TR Capital, in their respective investment as cornerstone investors in the US$414 million initial public offering and listing of Shanghai Junshi Biosciences Co., Ltd. on the Hong Kong Stock Exchange

• UBS AG, as financial adviser, in connection with the proposed US$671 million unsolicited conditional voluntary general offer by RE Strategic Investments Pte. Ltd., an entity associated with PAG Real Estate, to acquire all the units of Spring REIT

• Malaysian sovereign fund in its investment in the US$14 billion Series C equity financing of Ant Financial. This transaction was named Best China Deal and Best Financing (early stage to pre-IPO) by FinanceAsia Achievement Awards 2018 and Private Equity Deal of the Year by The Asia Legal Awards 2019

• Neoglory Prosperity Inc. (SZSE: 002147), in its potential acquisition of a controlling interest in, and the related takeover of, China High Speed Transmission Equipment Group Co., Ltd. (HKSE: 658)

2017

• MicroPort Scientific Corporation (HKSE: 853) in its US$190 million acquisition of the Cardiac Rhythm Management (CRM) business of NASDAQ-listed LivaNova PLC

• Alibaba Health Information Technology Limited (HKSE: 241) in its US$227 million issuance of new shares to a wholly-owned subsidiary of Alibaba Holding

• Midea International Corporation Company Limited, a wholly-owned subsidiary of Midea Group Co., Ltd. (000333.SZ), in its privatisation of Welling Holding Limited (HKSE: 382)

• Ally Bridge Group, as a joint offeror with a consortium established by an affiliate of the target company’s controlling shareholder and GL Capital Group, in its HK$2.34 billion (US$300 million) privatisation offer for the H shares of Shandong Luoxin Pharmaceutical Group (HKSE: 8058) by way of a voluntary conditional cash offer

• The Carlyle Group, CITIC Limited and CITIC Capital Holdings in the US$2.08 billion acquisition of the McDonald’s operations in China and Hong Kong and negotiation of a 20-year master franchise agreement ― the largest McDonald’s franchise in the world

2016

• COFCO Coca-Cola Beverages Limited, a subsidiary of Hong Kong-listed China Foods Limited (HKSE: 506) and a subsidiary of state-owned COFCO Corporation, in its acquisition of equity interests in the bottling operations from The Coca-Cola Company and Swire Beverages Holdings Limited, and in its sale through auction of its equity interests in the bottling operations in China

• Power Heritage Group Limited, in its proposed privatisation of Jiangnan Group (HKSE: 1366) by way of a scheme of arrangement

• Heaven-sent Capital, in its potential acquisition of a controlling interest in, and the related takeover of, Fulum Group (HKSE: 1443)

• J.P. Morgan, as financial adviser, in CVC Capital Partners-led funds’ US$1.1 billion privatisation of Nirvana Asia (HKSE: 1438) by way of a scheme of arrangement

• Ascendent Capital Partners, in connection with the HK$549 million acquisition of shares and subsequent HK$790 million conditional mandatory cash general offer by Araco Investment Limited for China Automation Group (HKSE: 569)

• Malaysian sovereign fund, in its investment in Alibaba’s logistics affiliate, Cainiao

• Malaysian sovereign fund (as lead investor), in its investment in a US$160 million Series B fundraising of WeLab, operator of Wolaidai, and WeLend.hk

2015

• China Grand Automotive Services Co., Ltd. (SSE: 600297), in its US$1.5 billion partial offer for Baoxin Auto Group (HKSE: 1293)

• Vipshop Holdings Limited (NYSE: VIPS), as a cornerstone investor, in its €30 million investment in the IPO of French online fashion retailer Showroomprive.com (IPO-SHOW.PA) on Euronext Paris

• China Traditional Chinese Medicine (HKSE: 570), in its HK$8.2 billion equity placing to its controlling shareholder Sinopharm and two executive directors, and 26 professional and institutional investors

• China Traditional Chinese Medicine (HKSE: 570), in its US$1.43 billion acquisition of a 87.30% stake in Jiangyin Tianjiang Pharmaceutical Co. Ltd.

• Pokka Corporation (Singapore), in its sale of Pokka Corporation (HK) and Pokka Coffee (Macau) to a majority-owned subsidiary of Xiao Nan Guo Restaurants Holdings (HKSE: 3666)

2014

• Shanghai Pudong Science and Technology Investment Co., Ltd., a state-owned enterprise under the direct administration of Pudong New Area government of Shanghai, in its US$693 million acquisition of NASDAQ-listed Montage Technology Group Limited, a global fabless provider of analog and mixed-signal semiconductor solutions addressing the home entertainment and cloud computing markets

• CCB International, in its purchase of secured notes and warrants issued by China Gui Tea Company Limited

• TPV Technology Limited (HKSE: 903), in its acquisition of the remaining 30% stake in TP Vision, the television joint venture with Koninklijke Philips N.V.

• 21st Century Fox, in its sale of a 49.9% stake in Star China TV to its joint venture partner, China Media Capital

2012–2013

• Beijing Wangfujing International, in its US$654 million (HK$5,099 million) acquisition of a controlling interest in, and the related takeover of, Hong Kong-listed PCD Stores (Group) Limited

• NCGA Holdings Limited, in its US$305 million acquisition by Baoxin Auto Group (HKSE: 1293)

• CITIC Securities Co., Limited (HKSE: 6030), in its purchase from Crédit Agricole Corporate & Investment Bank of CLSA B.V., an Asian equity brokerage, for US$1.252 billion. This deal was named "2012 M&A Deal of the Year (Outbound)" by China Business Law Journal and the "Best FIG Deal for 2013" by FinanceAsia

2011–2012

• TPV Technology Limited (HKSE: 903), in its acquisition of a 70% interest in a joint venture company which owns and controls the entire television business of Koninklijke Philips N.V. in Europe and certain South American countries

Prior to joining Kirkland & Ellis, Joey had represented:

• Shell Electric MFG. (Holdings) Company Limited (HKSE: 00081, now China Overseas Grand Oceans Group Ltd.), in its capital reduction, distribution in specie and group restructuring, and the related takeover offer by China Overseas Land & Investment Limited

• Telstra Corporation Limited (ASX: TLS), in its purchase of a 67% stake in Chinese mobiles audio and visual content and servicing business, China M and Sharp Point for US$259 million

• Shougang Fushan Resources Group Limited (HKSE: 639), in its purchase of a 14.34% stake in Mount Gibson Iron Limited (ASX: MGX) and a 16.8% stake in APAC Resources Limited (HKSE: 1104)

• APAC Resources Limited (HKSE: 1104), in underwriting and taking up its full entitlements in a A$96.5 million rights issue conducted by Mount Gibson Iron Limited (ASX: MGX)

• CITIC Capital Vanke China Property Fund, in its sale of a residential real estate project and properties in China

• Owners of Mondaine Watch Limited, in its acquisition of Hong Kong and mainland China-based watch and jewellery business of the EganaGoldpfeil group

• REA Group (ASX: REA), in its acquisition of Square Foot Limited and Primedia Limited, which engage in the publication of Hong Kong's English real estate magazine, "Square Foot", and lifestyle magazine, "Inside DB"

Skadden, Arps, Slate, Meagher & Flom (Hong Kong) — Associate, 2011

Mallesons Stephen Jaques (Hong Kong and Beijing) (now King & Wood Mallesons) — Trainee Solicitor, 2006–2008; Associate, 2008–2011